← Human Trials & Peer-Reviewed Studies
Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial
Plain-language guide to PMID 37929031 (2023): double-blind randomized controlled trial study of L-Carnitine in 46 women.
Key Facts
- PMID
- 37929031
- Journal
- Frontiers in endocrinology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Fallah F et al. (2 authors)
- DOI
- 10.3389/fendo.2023.1237882
What This Study Did, in Plain Language
What Was Tested
Researchers studied L-Carnitine in this randomized controlled trial publication.
This study was designed to assess the effects of L-carnitine single therapy compared with L-carnitine and multistrain/multispecies synbiotic co-supplementation on anthropometric and cardiometabolic indicators in women with obesity.
Why It Was Studied
Obesity, a multifactorial disorder with pandemic dimensions, is conceded a major culprit of morbidity and mortality worldwide, necessitating efficient therapeutic strategies.
Www.irct.ir, Iranian Registry of Clinical Trials IRCT20080904001197N13.
Who Took Part
The abstract describes 46 women taking part.
PubMed tags the participants as women only.
Participants in both groups received healthy eating dietary advice.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this L-Carnitine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the women and researchers unaware of who received L-Carnitine.
A placebo (an inactive look-alike) gave the L-Carnitine group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Cardiovascular Diseases, Carnitine, Iran, Lipids, Obesity and Synbiotics.
The authors tagged it with the keywords L-carnitine, anthropometric indices, cardiometabolic biomarkers, concomitant supplementation, glycemic parameters and lipid profile.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of L-Carnitine in 46 women.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (Frontiers in endocrinology), a journal based in Switzerland.
More context: the L-Carnitine compound page, all human trials.
Our Notes on the Compound
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.